Shanghai RAAS Blood Products Co., Ltd. (002252.SZ)
| Previous Close | 7.20 |
| Open | 7.22 |
| Bid | 7.18 x 0 |
| Ask | 7.19 x 0 |
| Day's Range | 7.14 - 7.25 |
| 52 Week Range | 5.93 - 8.68 |
| Volume | |
| Avg. Volume | 34,391,566 |
| Market Cap | 47.715B |
| Beta (5Y Monthly) | 0.43 |
| PE Ratio (TTM) | 25.64 |
| EPS (TTM) | 0.28 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.03 (0.42%) |
| Ex-Dividend Date | Jun 13, 2023 |
| 1y Target Est | N/A |
ReutersGrifols says Haier Group still OK to buy stake in Shanghai RAAS
Spanish pharma company Grifols said on Sunday evening Chinese home appliance maker Haier Group still plans to close the acquisition of a 20% stake in Shanghai RAAS Blood Products as announced in late December. Grifols currently owns 26.58% in Shanghai RAAS. Grifols quoted Haier Group's chairwoman saying: "We continue to work to close the deal as originally planned," in a filing to the Spanish stock market regulator.
ReutersGrifols shares soar after sale of 20% of Shanghai RAAS for $1.8 billion
MADRID/BEIJING (Reuters) -Shares in Spanish pharma group Grifols soared on Friday after it agreed to sell a 20% stake in China's Shanghai RAAS Blood Products for about $1.8 billion to Chinese home appliance company Haier Group Corporation. Grifols, which has been Shanghai RAAS's main shareholder, will retain a stake of 6.58% in the company. "With this transaction, Grifols is able to keep its presence in China, maintains its commercial agreements with SRAAS in place, and at the same time, complies with its commitment to deleverage," the Spanish company said on Friday.
